Cargando…
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing radiation (IR). In theory, more potent radiosensitizing drugs should increase tumour kill and improve patient outcomes....
Autores principales: | Adams, Stephen R., Yang, Howard C., Savariar, Elamprakash N., Aguilera, Joe, Crisp, Jessica L., Jones, Karra A., Whitney, Michael A., Lippman, Scott M., Cohen, Ezra E. W., Tsien, Roger Y., Advani, Sunil J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059467/ https://www.ncbi.nlm.nih.gov/pubmed/27698471 http://dx.doi.org/10.1038/ncomms13019 |
Ejemplares similares
-
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017) -
In Vivo
Targeting of Hydrogen Peroxide by Activatable
Cell-Penetrating Peptides
por: Weinstain, Roy, et al.
Publicado: (2013) -
Ratiometric Activatable Cell-Penetrating Peptides Provide Rapid In Vivo Readout of Thrombin Activation**
por: Whitney, Michael, et al.
Publicado: (2013) -
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012) -
Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
por: Lin, Tingting, et al.
Publicado: (2019)